1
|
Grimster NP, Gingipalli L, Balazs A, Barlaam B, Boiko S, Boyd S, Dry H, Goldberg FW, Ikeda T, Johnson T, Kawatkar S, Kemmitt P, Lamont S, Lorthioir O, Mfuh A, Patel J, Pike A, Read J, Romero R, Sarkar U, Sha L, Simpson I, Song K, Su Q, Wang H, Watson D, Wu A, Zehnder TE, Zheng X, Li S, Dong Z, Yang D, Song Y, Wang P, Liu X, Dowling JE, Edmondson SD. Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors. Bioorg Med Chem Lett 2023; 91:129352. [PMID: 37270074 DOI: 10.1016/j.bmcl.2023.129352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 04/25/2023] [Accepted: 05/26/2023] [Indexed: 06/05/2023]
Abstract
Spleen tyrosine kinase (SYK) is a non-receptor cytoplasmic kinase. Due to its pivotal role in B cell receptor and Fc-receptor signalling, inhibition of SYK has been a target of interest in a variety of diseases. Herein, we report the use of structure-based drug design to discover a series of potent macrocyclic inhibitors of SYK, with excellent kinome selectivity and in vitro metabolic stability. We were able to remove hERG inhibition through the optimization of physical properties, and utilized a pro-drug strategy to address permeability challenges.
Collapse
Affiliation(s)
| | | | | | | | | | - Scott Boyd
- Oncology R & D, AstraZeneca, Cambridge, UK
| | - Hannah Dry
- Oncology R & D, AstraZeneca, Waltham, USA
| | | | - Tim Ikeda
- Discovery Sciences R & D, AstraZeneca, Waltham, USA
| | | | | | | | | | | | | | - Joe Patel
- Discovery Sciences R & D, AstraZeneca, Waltham, USA
| | - Andy Pike
- Oncology R & D, AstraZeneca, Cambridge, UK
| | - Jon Read
- Discovery Sciences R & D, AstraZeneca, Cambridge, UK
| | | | | | - Li Sha
- Oncology R & D, AstraZeneca, Waltham, USA
| | | | - Kun Song
- Oncology R & D, AstraZeneca, Waltham, USA
| | - Qibin Su
- Oncology R & D, AstraZeneca, Waltham, USA
| | | | | | - Allan Wu
- Discovery Sciences R & D, AstraZeneca, Waltham, USA
| | | | | | - Shaolu Li
- Oncology R & D, AstraZeneca, Waltham, USA
| | - Zhiqiang Dong
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | - Dejian Yang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | - Yanwei Song
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | - Peng Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | - Xuemei Liu
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | | | | |
Collapse
|
2
|
Tang S, Yu Q, Ding C. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases. Expert Opin Investig Drugs 2022; 31:291-303. [PMID: 35130124 DOI: 10.1080/13543784.2022.2040014] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
INTRODUCTION Autoimmune diseases (ADs) are disorders induced by multiple inflammatory mediators, in which immune system attacks healthy tissues and triggers tissue injury. Targeted regulation of the activity of kinases that influence inflammation is one of the major therapies for ADs. Recently, investigational spleen tyrosine kinase (SYK) inhibitors have shown encouraging results in the ADs therapy. AREAS COVERED This article provides a background on autoimmune diseases and provides an update on investigational SYK inhibitors. This literature review was conducted by searching publications about investigational Spleen tyrosine kinase inhibitors in the treatment of ADs from experimental to clinical studies. The search terms used were SYK inhibitors, R406, fostamatinib (R788), P505-15 (PRT062607), entospletinib (GS-9973), R112, lanraplenib (GS-9876), cerdulatinib, R343, BAY-61-3606, GSK compound 143 (GSK143), R211, SKI-G-618, SKI-O-85, ER-27319, YM193306, RO9021 in conjunction with autoimmune disease using electronic databases including PubMed, EMBASE, MEDLINE and Google Scholar. EXPERT OPINION SYK inhibitors are promising drugs with unique advantages and acceptable tolerability and safety for the treatment of ADs. However, the difficulties in developing highly selective SYK inhibitors and the unknown effects are challenges. Long term and real-world data are essential to determine the risk-benefit ratio and true role of SYK inhibitors in the therapy of ADs.
Collapse
Affiliation(s)
- Su'an Tang
- Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.,Centre of Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Qinghong Yu
- Department of Rheumatology and Clinical Immunology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
| | - Changhai Ding
- Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.,Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
3
|
2-(2-Amino-6-methylpyrimidin-4-yl)-4-arylmethylidene- 5-methyl-2,4-dihydro-3H-pyrazol-3-ones: Design, synthesis, structure, in vitro anti-tubercular activity, and molecular docking study. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2021.130863] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
4
|
Barlaam B, Boiko S, Boyd S, Dry H, Gingipalli L, Ikeda T, Johnson T, Kawatkar S, Lorthioir O, Pike A, Pollard H, Read J, Su Q, Wang H, Wang H, Wang L, Wang P, Edmondson SD. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors. Bioorg Med Chem Lett 2020; 30:127523. [PMID: 32877741 DOI: 10.1016/j.bmcl.2020.127523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 08/20/2020] [Accepted: 08/24/2020] [Indexed: 10/23/2022]
Abstract
Hybridisation of amino-pyrimidine based SYK inhibitors (e.g. 1a) with previously reported diamine-based SYK inhibitors (e.g. TAK-659) led to the identification and optimisation of a novel pyrimidine-based series of potent and selective SYK inhibitors, where the original aminomethylene group was replaced by a 3,4-diaminotetrahydropyran group. The initial compound 5 achieved excellent SYK potency. However, it suffered from poor permeability and modest kinase selectivity. Further modifications of the 3,4-diaminotetrahydropyran group were identified and the interactions of those groups with Asp512 were characterised by protein X-ray crystallography. Further optimisation of this series saw mixed results where permeability and kinase selectivity were increased and oral bioavailability was achieved in the series, but at the expense of potent hERG inhibition.
Collapse
Affiliation(s)
| | - Scott Boiko
- R&D Oncology, AstraZeneca, Boston, MA, United States
| | - Scott Boyd
- R&D Oncology, AstraZeneca, Cambridge, United Kingdom
| | - Hannah Dry
- R&D Oncology, AstraZeneca, Boston, MA, United States
| | | | - Timothy Ikeda
- R&D Oncology, AstraZeneca, Boston, MA, United States
| | - Tony Johnson
- R&D Oncology, AstraZeneca, Cambridge, United Kingdom
| | | | | | - Andy Pike
- R&D Oncology, AstraZeneca, Cambridge, United Kingdom
| | - Hannah Pollard
- Discovery Sciences, AstraZeneca, Cambridge, United Kingdom
| | - Jon Read
- Discovery Sciences, AstraZeneca, Cambridge, United Kingdom
| | - Qibin Su
- R&D Oncology, AstraZeneca, Boston, MA, United States
| | - Haiyun Wang
- R&D Oncology, AstraZeneca, Boston, MA, United States
| | - Huimin Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | - Lianghe Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | - Peng Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China
| | | |
Collapse
|
5
|
Grimster NP, Gingipalli L, Barlaam B, Su Q, Zheng X, Watson D, Wang H, Simpson I, Pike A, Balazs A, Boiko S, Ikeda TP, Impastato AC, Jones NH, Kawatkar S, Kemmitt P, Lamont S, Patel J, Read J, Sarkar U, Sha L, Tomlinson RC, Wang H, Wilson DM, Zehnder TE, Wang L, Wang P, Goldberg FW, Shao W, Fawell S, Dry H, Dowling JE, Edmondson SD. Optimization of a series of potent, selective and orally bioavailable SYK inhibitors. Bioorg Med Chem Lett 2020; 30:127433. [DOI: 10.1016/j.bmcl.2020.127433] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 06/22/2020] [Accepted: 07/21/2020] [Indexed: 12/25/2022]
|
6
|
Ganjoo A, Prabhakar C. In silico structural anatomization of spleen tyrosine kinase inhibitors: Pharmacophore modeling, 3D QSAR analysis and molecular docking studies. J Mol Struct 2019. [DOI: 10.1016/j.molstruc.2019.04.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
7
|
Novel N-thioamide analogues of pyrazolylpyrimidine based piperazine: Design, synthesis, characterization, in-silico molecular docking study and biological evaluation. J Mol Struct 2019. [DOI: 10.1016/j.molstruc.2018.08.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
8
|
Lee SJ, Choi JS, Bong SM, Hwang HJ, Lee J, Song HJ, Lee J, Kim JH, Koh JS, Lee BI. Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors. Mol Cells 2018; 41:545-552. [PMID: 29890824 PMCID: PMC6030240 DOI: 10.14348/molcells.2018.2219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Revised: 03/01/2018] [Accepted: 04/06/2018] [Indexed: 11/27/2022] Open
Abstract
Spleen tyrosine kinase (SYK) is a cytosolic non-receptor protein tyrosine kinase. Because SYK mediates key receptor signaling pathways involving the B cell receptor and Fc receptors, SYK is an attractive target for autoimmune disease and cancer treatments. To date, representative oral SYK inhibitors, including fostamatinib (R406 or R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659, have been assessed in clinical trials. Here, we report the crystal structures of SYK in complex with two newly developed inhibitors possessing 4-aminopyrido[4,3-D]pyrimidine moieties (SKI-G-618 and SKI-O-85). One SYK inhibitor (SKI-G-618) exhibited moderate inhibitory activity against SYK, whereas the other inhibitor (SKI-O-85) exhibited a low inhibitory profile against SYK. Binding mode analysis indicates that a highly potent SYK inhibitor might be developed by modifying and optimizing the functional groups that interact with Leu377, Gly378, and Val385 in the G-loop and the nearby region in SYK. In agreement with our structural analysis, one of our SYK inhibitor (SKI-G-618) shows strong inhibitory activities on the β-hexosaminidase release and phosphorylation of SYK/Vav in RBL-2H3 cells. Taken together, our findings have important implications for the design of high affinity SYK inhibitors.
Collapse
Affiliation(s)
- Sang Jae Lee
- Research Institute, National Cancer Center, Goyang, Gyeonggi 10408,
Korea
- The Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826,
Korea
| | | | - Seoung Min Bong
- Research Institute, National Cancer Center, Goyang, Gyeonggi 10408,
Korea
| | | | | | - Ho-Juhn Song
- Genosco, 767C Concord Ave, 2nd Floor, Cambridge, MA 02138,
USA
| | - Jaekyoo Lee
- Genosco, 767C Concord Ave, 2nd Floor, Cambridge, MA 02138,
USA
| | | | - Jong Sung Koh
- Genosco, 767C Concord Ave, 2nd Floor, Cambridge, MA 02138,
USA
| | - Byung Il Lee
- Research Institute, National Cancer Center, Goyang, Gyeonggi 10408,
Korea
| |
Collapse
|
9
|
Lee SJ, Choi JS, Han BG, Kim HS, Song HJ, Lee J, Nam S, Goh SH, Kim JH, Koh JS, Lee BI. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs. FEBS J 2016; 283:3613-3625. [DOI: 10.1111/febs.13831] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 07/04/2016] [Accepted: 08/08/2016] [Indexed: 11/27/2022]
Affiliation(s)
- Sang Jae Lee
- Research Institute; National Cancer Center; Goyang Gyeonggi Korea
- The Research Institute of Pharmaceutical Sciences; College of Pharmacy; Seoul National University; Korea
| | | | - Byeong-Gu Han
- Research Institute; National Cancer Center; Goyang Gyeonggi Korea
| | - Hyoun Sook Kim
- Research Institute; National Cancer Center; Goyang Gyeonggi Korea
| | | | | | - Seungyoon Nam
- Department of Life Sciences; College of BioNano Technology; Gachon University; Sungnam Korea
- Department of Genome Medicine and Science; Graduate School of Medicine; Gachon University; Incheon Korea
| | - Sung-Ho Goh
- Research Institute; National Cancer Center; Goyang Gyeonggi Korea
| | | | | | - Byung Il Lee
- Research Institute; National Cancer Center; Goyang Gyeonggi Korea
| |
Collapse
|
10
|
Choi H, Kim J, Lee K. Metal-free, Brønsted acid-mediated synthesis of coumarin derivatives from phenols and propiolic acids. Tetrahedron Lett 2016. [DOI: 10.1016/j.tetlet.2016.06.039] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Yong WS, Park S, Yun H, Lee PH. Synthesis of 2H-IndazolesviaTandem Palladium-Catalyzed Deacylative Cross-Coupling and Denitrogenative Cyclization of 2-Iodoazoarenes and 2-Iodoaryltriazenes with Acyldiazoacetates in One-Pot. Adv Synth Catal 2016. [DOI: 10.1002/adsc.201600351] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
12
|
Meyer F. Trifluoromethyl nitrogen heterocycles: synthetic aspects and potential biological targets. Chem Commun (Camb) 2016; 52:3077-94. [DOI: 10.1039/c5cc09414c] [Citation(s) in RCA: 108] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The synthetic methodologies and the potential biological targets of α-trifluoromethylated nitrogen heterocycles are presented.
Collapse
Affiliation(s)
- F. Meyer
- Laboratory of Biopolymers and Supramolecular Nanomaterials
- Faculty of Pharmacy
- Université Libre de Bruxelles (ULB)
- 1050 Bruxelles
- Belgium
| |
Collapse
|